Group items tagged

"The Data Protection Act demands that organisations treat individuals' sensitive personal data with utmost privacy as this data attracts specific protection under the Act, and in addition, patient confidentiality must be maintained at all times," Ross Eckford said. "In effect this means that mobile devices used to store, access or transmit patient data must be secure and not capable of being accessed by unauthorised individuals."

"Data transmissions should also be encrypted and secure to prevent data being intercepted, and, in accordance with the Act, the information should only be processed for specified purposes, such as to input data about a patient onto a server containing their medical records or to send a patient a text reminder about hospital appointments," she added.

One project would be to standardize the way data from clinical trials are recorded. That would make it easier for clinical trial investigators to enter data without having to remember each company’s format and to compare data from clinical trials. Similarly, TransCelerate will work on a common Internet portal that investigators can use to communicate with all drug companies, and also on standardizing efforts to qualify clinical trial sites and to train investigators. It will also work on a way for companies to easily procure one another’s already marketed drugs for use in comparative clinical trials.

 A titre personnel, ça ne m'emballe pas du tout, estime Francis Lévi, membre de l'Académie des technologies et directeur de l'unité rythmes biologiques et cancers de l'Inserm. D'abord parce que l'idée d'établir des arbres de décision personnalisés aboutit au risque de faire de la médecine sans médecins. Ensuite parce que les données publiées dans la littérature médicale ne reflètent pas forcément la réalité de la médecine, car elles correspondent à des patients correspondant aux critères de l'étude

 Il n'y a pas de frein technologique aux outils d'aide au diagnostic, mais il y a deux domaines fondamentaux : la sécurité des données, qui ne doivent être ni communiquées ni modifiées par un tiers. Mais aussi la formation des médecins et des usagers : il faudra expliquer ces nouveaux outils pour que chacun comprenne leurs limites. »

« Pour créer de meilleurs outils d'aide au diagnostic, il faudra arriver à trouver une structuration commune à toutes les pratiques médicales, ce qui est loin d'être le cas », estime Pierre-Henri Comble

ARTO™, a complete Patient Risk Management Solution, helps healthcare providers unlock more value from their electronic medical data. Using both structured and unstructured data, our solutions provide actionable insights that translate directly into lower costs and better outcomes.

Healthcare is moving from a volume model ("fee-for-service") to a value model ("fee-for-value") in which care providers will become financially at-risk for patient costs. Advanced analytics solutions can help these at-risk providers better understand their costs and optimize resource allocation to manage them. Case Management offers a particularly high potential return for optimization.

healthcare practitioners (HCPs)

1. Managed care-driven2. Patient-driven3. Technology-driven

The following questions are being tested in industry research to better characterize the new influences and to set up more insightful metrics of brand performance: How does the influence affect the strength of the relationship between the prescriber, company, and brand?  Can relationships with HCPs be strengthened by indirect influences, such as social media?  Regular assessment of relationship strength and corresponding value delivered is critical for brands operating under new commercial models. How does the influence support or contradict the brand's value proposition?  One metric to consider is believability of the brand's message in light of new influences being exercised. For example, peer-to-peer experiential dialog via the Internet may substantiate or significantly weaken the brand's claims. A metric of "customer alignment" is required and can be quantified by mining the dialog. To what extent does the influence help or hurt company communication and education efforts, including personal promotion?  The emergence of widely accessible technologies for sharing information has the potential to spread incomplete, biased, or worse, inaccurate information, which may change the nature of discussions between reps and HCPs. Field organizations must understand and address misconceptions and objections that develop more quickly in today's highly-connected environment. At the heart of today's influences are two related goals: containing costs and understanding comparative effectiveness. Measurement programs need to consider both these drivers to effectively evaluate brand performance. Measuring the impact of a pharmaceutical

The other 3 fixes LaMattina put on a par with dropping TV ads are Transparency of payments to healthcare professionals,  Transparency of clinical trial data, and  Stop the illegal detailing of drugs 

Ten leading biopharmaceutical companies announced today that they have formed a non-profit organization to accelerate the development of new medicines. Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech a member of the Roche Group, and Sanofi launched TransCelerate BioPharma Inc. ("TransCelerate"), the largest ever initiative of its kind, to identify and solve common drug development challenges with the end goals of improving the quality of clinical studies and bringing new medicines to patients faster.

financial and other resources, including personnel, to solve industry-wide challenges in a collaborative environment.

among the heads of R&D at major pharmaceutical companies that there is a critical need to substantially increase the number of innovative new medicines,

Le marketing via les canaux digitaux a augmenté de 65% aux États-Unis l'an dernier et de 40% dans les grands pays d'Europe, constate une étude de Cegedim Strategic Data (CSD) sur l'investissement promotionnel des laboratoires pharmaceutiques en 2012. Aux États-Unis, les laboratoires investissent près d'un milliard de dollars dans ces nouveaux outils. Les Européens en sont très loin, avec 90 millions de dollars seulement dépensés en e-marketing en Allemagne, Grande-Bretagne, France, Espagne et Italie. Un retard dû, dans l'Hexagone notamment, aux réticences des médecins face à l'ordinateur, observe Christopher Wooden, vice-président chez CSD.

La visite médicale n'est pas, pour autant, condamnée. Elle a diminué de plus de 10% en Europe et aux États-Unis en 2012, mais elle a augmenté de 20% en Chine et 7% au Brésil. Les dépenses mondiales de promotion se sont d'ailleurs stabilisées en 2012 à 90 milliards de dollars, dont la moitié aux États-Unis et en Europe.

Voici 9 éléments qui poussent aujourd’hui la santé à se connecter cette année : 1. Une technologie Mature 2. Une priorité pour tous, la Santé 3. Le chaudron de la connectivité 4. La santé digitale est attrayante 5. Les hommes veulent être acteur de leur santé 6. L’industrie pharmaceutique est en recherche d’un nouveau modèle d’affaires 7. La Big data et le Dossier Médical Personnel 8. Un beau marché est à conquérir 9. Des acteurs importants provenant de secteurs complémentaires sont dans les starting-block